产品名称 | NebuSelect™ Recombinant Biotinylated Human SLAMF1/SLAM/CD150, Avi-His-tag |
---|---|
目录号 | NBL-242090 |
别名 | SLAMF1/SLAM/CD150; CDw150; IPO-3; CD150; SLAMF1; SLAM |
外观 | see COA |
分子量 | Ala21-Pro237 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q13291-1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242090-100ug | 100ug | Inquire | Inquire | |
NBL-242090-1mg | 1mg | Inquire | Inquire | |
NBL-242090-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Biotinylated Human SLAMF1/SLAM/CD150, Avi-His-tag
Catalog#:
NBL-242090
Description:
NebuSelect™ Recombinant Biotinylated Human SLAMF1/SLAM/CD150, Avi-His-tag(Cat#NBL-242090) is expressed in HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala21-Pro237.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 27.2 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Target Name:
SLAMF1/SLAM/CD150; CDw150; IPO-3; CD150; SLAMF1; SLAM
Target Information:
SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myeloma.
Amino Acid Sequence:
Ala21-Pro237
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.